A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPRER axis
Open accessThe DOI matches its Crossref record; 61 of the 64 references it cites were found in a registry or an index.
Abstract
Hypoxic tumor microenvironment (TME) plays critical roles in induction of cancer stem cell-like phenotype in breast cancer and contribute to chemoresistance. However, the mechanism underlying stemness reprogramming of breast cancer cells (BCs) by hypoxic TME remains largely unknown. In the present study, we illustrated that HIF-2α, but not HIF-1α, induces stemness in BCs under hypoxia through SOD2-mtROS-PDI/GRP78-UPR ER pathway, linking mitochondrial metabolic state to endoplasmic reticulum (ER) response via mitochondrial reactive oxygen species (mtROS) level. HIF-2α activates endoplasmic reticulum unfolded protein response (UPR ER) in drug-sensitive MCF7 and T47D cells to induce drug-resistant stem-like phenotype. Genetic depletion or pharmacological inhibition (YQ-0629) of HIF-2α abolished hypoxia-induced stem-like phenotype in vitro and in vivo. Mechanistically, HIF-2α activates transcription of superoxide dismutase 2 (SOD2) under hypoxia and thereby decreases mtROS level. With less mtROS transported to endoplasmic reticulum, the expression and activity of protein disulfide isomerase (PDI) is suppressed, allowing glucose-regulated protein 78 (GRP78) to dissociate from receptor proteins of UPR ER and bind misfolded protein to activate UPR ER, which eventually confer chemoresistance and stem-like properties to BCs. Moreover, the increase in mtROS and PDI levels caused by HIF-2α knockdown and the subsequent UPR ER inhibition could be substantially rescued by mitoTEMPOL (a mtROS scavenger), 16F16 (a PDI inhibitor), or GRP78 overexpression. Overall, we reported the critical roles of HIF-2α-SOD2-mtROS-PDI/GRP78-UPR ER axis in mediating hypoxia-induced stemness in BCs, highlighting the interaction between organelles and providing evidence for further development of targeted HIF-2α inhibitor as a promising therapeutic strategy for chemoresistant breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Continued efforts are now focused on developing next-generation HIF-2α inhibitors with enhanced selectivity and potency, such as YQ-0629 and casdatifan (AB521), both of which have shown promising preclinical and early clinical activity [[418], [419], [420]].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [418]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“HIF-2α mediated antioxidant gene expression protects pancreatic β-cells against glucotoxicity in the context of obesity, whereas in breast cancer, this HIF-2α mediated reduction in mitochondrial ROS is associated with increased chemoresistance and stem-like properties [50, 51].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Samanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460
RetractedThe unfolded protein response: controlling cell fate decisions under ER stress and beyond
Hetz, C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3270 · Cited by 4,093
Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?
Sabharwal, S. S., & Schumacker, P. T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3803 · Cited by 1,622
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
Zhang, C., Samanta, D., Lu, H., Bullen, J. W., Zhang, H., Chen, I., He, X., & Semenza, G. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602883113 · Cited by 971
Covello, K. L., Kehler, J., Yu, H., Gordan, J. D., Arsham, A. M., Hu, C.-J., Labosky, P. A., Simon, M. C., & Keith, B. (2006) · Genes & Development · doi:10.1101/gad.1399906 · Cited by 821
HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity
Gordan, J. D., Bertout, J. A., Hu, C.-J., Diehl, J. A., & Simon, M. C. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.006 · Cited by 781
Metabolic Reprogramming: the Emerging Concept and Associated Therapeutic Strategies
Yoshida, G. J. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0221-y · Cited by 716
Targeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature · doi:10.1038/nature19796 · Cited by 709
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
Cited by
Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer
Bae, T., Hallis, S. P., & Kwak, M.-K. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01180-8 · Cited by 354
Redox regulation: mechanisms, biology and therapeutic targets in diseases
Li, B., Ming, H., Qin, S., Nice, E. C., Dong, J., Du, Z., & Huang, C. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02095-6 · Cited by 317
Li, G., Wang, D., Zhai, Y., Pan, C., Zhang, J., Wang, C., Huang, R., Yu, M., Li, Y., Liu, X., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.07.011 · Cited by 232
Alleviating hypoxia to improve cancer immunotherapy
Fan, P., Zhang, N., Candi, E., Agostini, M., Piacentini, M., Bernassola, F., Bove, P., Alessandro, M., Giuseppe, N., Valentina, R., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02869-2 · Cited by 104
Self-citationp63: a crucial player in epithelial stemness regulation
Li, Y., Giovannini, S., Wang, T., Fang, J., Li, P., Shao, C., Wang, Y., Agostini, M., Bove, P., Mauriello, A., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02859-4 · Cited by 93
Self-citation
Metadata
- Authors
- Yan, Y., He, M., Zhao, L., Wu, H., Zhao, Y., Han, L., Wei, B., Ye, D., Lv, X., Wang, Y., Yao, W., Zhao, H., Chen, B., Jin, Z., Wen, J., Zhu, Y., Yu, T., Jin, F., & Wei, M.
- Affiliations
- China Medical University (CN)
- Liaoning Cancer Hospital & Institute (CN)
- First Hospital of China Medical University (CN)
- Fourth Affiliated Hospital of China Medical University (CN)
- Corresponding author
- Yu, Tao
- Jin, Feng
- Wei, Minjie
- ORCID
- Venue
- Cell Death & Differentiation
- Published
- 2022-03-17
- Volume
- 29
- Issue
- 9
- Pages
- 1769-1789
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- PMC
- PMC9433403
- OpenAlex
- W4220868035
- Cited by
- 101
- References
- 64
- Citations by year
- 2026: 19 · 2025: 35 · 2024: 21 · 2023: 21 · 2022: 5
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death and Differentiation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81902708, 2019JH8, U20A20413, 81972794, 81373427, 81702616)
- China Medical University
- National Natural Science Foundation of China-Liaoning Joint Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- HIF-2α, breast cancer stemness, hypoxia, tumor microenvironment, manganese superoxide dismutase, mitochondrial reactive oxygen species, PDI, GRP78, unfolded protein response, chemoresistance, HIF-2α inhibitor, PDI inhibitors
- MeSH terms
- Superoxide Dismutase 2, Hypoxia, Endoplasmic Reticulum, Humans, Neoplasms, Superoxides, Superoxide Dismutase, Protein Disulfide-Isomerases, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPRER axis. https://app.cochat.ai/papers/10.1038/s41418-022-00963-8
- The paper
- Yan, Y., He, M., Zhao, L., Wu, H., Zhao, Y., Han, L., Wei, B., Ye, D., Lv, X., Wang, Y., Yao, W., Zhao, H., Chen, B., Jin, Z., Wen, J., Zhu, Y., Yu, T., Jin, F., & Wei, M. (2022). A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPRER axis. Cell Death & Differentiation. https://doi.org/10.1038/s41418-022-00963-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.